Even in MSI CRCs, which are known to show favorable outcomes independent of KRAS or BRAF status,20 SARIFA-positivity seemed to be associated with a worse CRC-specific (P=0.063) and reduced overall survival (P=0.161). This evidence concerns the gene BRAF and colorectal carcinoma.